Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1426-1434

  Gatza, Erin ^a,b   Braun, Thomas ^a   Levine, John E ^a,b   Ferrara, James L M ^a,b   Zhao, Shuang ^a,b   Wang, Tianyi ^a,b   Chang, Lawrence ^a,b   Harris, Andrew ^a,b   Pawarode, Attaphol ^a,b   Kitko, Carrie ^a,b   Magenau, John M ^a,b   Yanik, Gregory A ^a,b   Couriel, Daniel R ^a,b   Goldstein, Steven ^a,b   Connelly, James ^a,b   Reddy, Pavan ^a,b   Paczesny, Sophie ^c   Choi, Sung Won ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Clinical trial; Etanercept; Grade 1 acute; Graft versus host disease; Hematopoietic stem cell transplantation

Indexed keywords

BIOLOGICAL MARKER; ETANERCEPT; TRIAMCINOLONE; GLUCOCORTICOID; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARCINOGENICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RELAPSE; SCHOOL CHILD; SURVIVAL RATE; YOUNG ADULT; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; COHORT ANALYSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; PROSPECTIVE STUDY;

ACUTE DISEASE; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84905565069     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.023     Document Type: Article

References (39)

1. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
2. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
4. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
5. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
6. Storb R., Gyurkocza B., Storer B.E., et al. Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. Biol Blood Marrow Transplant 2013, 19:792-798.
7. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. JClin Oncol 2013, 31:1530-1538.
8. Alousi A.M., Bolanos-Meade J., Lee S.J. Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant 2013, 19:S102-S108.
9. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
10. Hings I.M., Severson R., Filipovich A.H., et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994, 58:437-442.
11. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
12. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
13. Weisdorf D.J., Snover D.C., Haake R., et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990, 76:624-629.
14. Levine J.E., Logan B., Wu J., et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010, 16:1693-1699.
15. MacMillan M.L., DeFor T.E., Weisdorf D.J. The best endpoint for acute GVHD treatment trials. Blood 2010, 115:5412-5417.
16. Saliba R.M., Couriel D.R., Giralt S., et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012, 47:125-131.
17. Westin J.R., Saliba R.M., De Lima M., et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011, 2011:601953.
18. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
19. Kitko C.L., Paczesny S., Yanik G., et al. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant 2008, 14:759-765.
20. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
21. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. JImmunol 2000, 164:656-663.
22. Korngold R., Marini J.C., de Baca M.E., et al. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003, 9:292-303.
23. Korth-Bradley J.M., Rubin A.S., Hanna R.K., et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000, 34:161-164.
24. Choi S.W., Stiff P., Cooke K., et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant 2012, 18:1525-1532.
25. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. JClin Microbiol 2004, 42:1142-1148.
26. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
27. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
28. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
29. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. NEngl J Med 2013, 369:529-539.
30. Ferrara J.L., Harris A.C., Greenson J.K., et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118:6702-6708.
31. Paczesny S., Braun T.M., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010, 2:13ra2.
32. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
33. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
34. ASBMT RFI 2013-Disease Classifications Corresponding to CIBMTR Classifications. 2013. Available at http://c.ymcdn.com/sites/www.asbmt.org/resource/resmgr/Docs/ASBMT_RFI_2014_Translation_t.pdf.
35. Harris A.C., Ferrara J.L., Braun T.M., et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119:2960-2963.
36. Levine J.E., Logan B.R., Wu J., et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012, 119:3854-3860.
37. Paczesny S., Krijanovski O.I., Braun T.M., et al. Abiomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
38. Levine J.E., Paczesny S., Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:S116-S124.
39. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013, 121:585-594.